bevacizumab
roche
['beva', 'rectal', 'bevacizumab', 'colorectal']
#cedarssinaicancer at #asco22. is co-author on phase 1b study of rgx-202-01, a first-in-class oral inhibitor of the slc6a8/ckb pathway, in combination with folfiri &amp; bevacizumab in second-line advanced #colorectalcancer. 
Cedars-Sinai Cancer, ranked #9 in the nation in 2021 by U.S. News & World Report.